Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.

Current Report (Form 8-K | Period ending 2024-05-24)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Relmada Therapeutics (RLMD US)

Current Report (Form 8-K | Period ending 2024-05-24)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Current Report (Form 8-K | Period ending 2024-03-19)

Annual Report (Form 10-K | Period ending 2023-12-31)

Statement of changes in beneficial ownership (Form 4 | Period ending 2024-01-29)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)